Top Markets
Coin of the day
Provention Bio, Inc. Provention Bio, Inc.

Provention Bio, Inc.

PRVB
주식 순위 #9449
Provention Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Provention Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and bringing to market therapies aimed at intercepting and preventing autoimmune disorders. Their lead investigational candidate, PRV-031 (teplizumab, a monoclonal antibody), is currently in a Phase III clinical trial for the interception of Type 1 Diabetes (T1D). Another asset, PRV-3279, has successfully completed its Phase Ib clinical trial for the treatment of lupus. The company is also developing PRV-101, a vaccine targeting coxsackie virus B (CVB) to prevent both acute CVB infections and the onset of T1D. Additionally, PRV-015 is undergoing a Phase IIb clinical trial, offering a potential treatment for celiac disease that does not respond to a gluten-free diet. Provention Bio has established strategic partnerships to advance its pipeline. This includes a licensing and collaboration agreement with Amgen Inc. for PRV-015, described as a novel anti-IL-15 monoclonal antibody, for the continued development against gluten-free diet non-responsive celiac disease. Furthermore, a strategic alliance with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. focuses on the development and commercialization of PRV-3279 in Greater China. PRV-3279 is characterized as a bispecific antibody-based molecule designed to target B cell surface proteins CD32B and CD79B. Founded in 2016, Provention Bio, Inc. maintains its headquarters in Red Bank, New Jersey.
주가
$24.98
마지막 동기화: 2023-04-27
시가총액
$1.01B
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Provention Bio, Inc. (PRVB)

카테고리

Provention Bio, Inc. (PRVB)의 주가 이력
최고 종가: $24.40 (2023-04-01 기준)

최저 종가: $4.34 (2018-07-01 기준)
Provention Bio, Inc.의 주가 이력 (2018 ~ 2026)
연간 주가 성과
연도 성과
2023 158.40%
2022 53.04%
2021 -64.36%
2020 44.04%
2019 443.29%
2018 0.00%
유사 기업 또는 경쟁사의 주가
회사 주가 변동률 1년% 국가
$542.09 38.63%
US
$1.03K 44.13%
NL
$121.53 -12.70%
AU
$138.18 473.58%
US
$759.27 7.20%
CH